Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. Absent, impaired, or rare ovulation induces progesterone deficiency in the luteal phase, which is a critical problem in PCOS. A usual pattern of progesterone administration from a fixed and arbitrary pre-determined day of a menstrual cycle may preserve infertility but can easily be avoided. We present the case of a 29-year-old infertile woman who had been ineffectively treated for over two years. We introduced a line of therapy that was suited to her individual menstrual cycle by implementing biomarker recording. Supplementation based on a standardized observation of the basal body temperature (BBT) and cervical mucus stopped the vicious circle of absent ovulation and hyperandrogenism, restoring regular bleeding, ovulation cycles, and fertility. The implementation of a reliable fertility awareness method (FAM), accompanied by a standardized teaching methodology and periodic review of the observations recorded by the patient, validated through an ultrasound examination and plasma gonadotropins, estrogens, and progesterone concentrations, is key to achieving therapeutic success. The presented case is an example of a clinical vignette for many patients who have successfully managed to improve their fertility and pregnancy outcomes by applying the principles of a personalized treatment approach together with gestagens by recording their fertility biomarkers.
Kicińska, A. M., Stachowska, A., Kajdy, A., Wierzba, T. H., & Maksym, R. B. (2023). Successful Implementation of Menstrual Cycle Biomarkers in the Treatment of Infertility in Polycystic Ovary Syndrome-Case Report. *Healthcare (Basel, Switzerland)*, *11*(4), 616. https://doi.org/10.3390/healthcare11040616
Kicińska AM, Stachowska A, Kajdy A, Wierzba TH, Maksym RB. Successful Implementation of Menstrual Cycle Biomarkers in the Treatment of Infertility in Polycystic Ovary Syndrome-Case Report. Healthcare (Basel). 2023;11(4):616. doi:10.3390/healthcare11040616
Kicińska, A. M., et al. "Successful Implementation of Menstrual Cycle Biomarkers in the Treatment of Infertility in Polycystic Ovary Syndrome-Case Report." *Healthcare (Basel, Switzerland)*, vol. 11, no. 4, 2023, pp. 616.
Shirin S et al., 2021
Open Access
Medicina (Kaunas, Lithuania)
Background and Objectives: Women with androgenic Polycystic Ovary Syndrome (PCOS) have increased endometrial cancer risk that cyclic progesterone will prevent; it may also reverse PCOS's neuroendocrin...
Shirin S et al., 2020
Open Access
Journal of the Endocrine Society
Endometrial cancer1 and oligomenorrhea2 are common risks for women living with androgenic PCOS (WLWP); cyclic progesterone therapy could prevent both. Cyclic oral micronized progesterone therapy (Cycl...
Nelson K et al., 2025
Open Access
Journal of the Endocrine Society
Disclosure: K. Nelson: None. J. Singer: None. A. Pederson: None. D. Kalidasan: None. J. Prior: None.
Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder that significantly decreases he...
Boyle PC et al., 2024
Open Access
Frontiers in Medicine
Hypoandrogenemia is not usually considered as a potential cause of recurrent miscarriage. We present the case of a 30-year-old female with 6 previous pregnancies resulting in one live birth and 5 preg...